AbbVie Inc. (ABBV) Return on Equity (ROE): -129.24%
Is AbbVie Inc.’s return on equity (ROE) high or low?
AbbVie Inc.'s return on equity (ROE) of -129.24% is 444% below its 5-year average of 37.53%, near the low end of its 5-year range (-129.24%–128.66%).
The return on equity (ROE) for AbbVie Inc. (ABBV) is -129.24% as of Tuesday, June 9, 2026. It is below its 12-month average by 44465.52% (-0.29%).
ABBV Return on Equity (ROE) Chart
ABBV Average Return on Equity (ROE) Chart
ABBV Current vs Average Return on Equity (ROE) Chart
ABBV Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
-129.24%
RETURN ON EQUITY (ROE) AVG TTM
-0.29%
RETURN ON EQUITY (ROE) AVG 3Y
28.74%
RETURN ON EQUITY (ROE) AVG 5Y
37.53%
RETURN ON EQUITY (ROE) AVG 10Y
38.58%
RETURN ON EQUITY (ROE) AVG 15Y
51.89%
RETURN ON EQUITY (ROE) AVG 20Y
48.84%
CURRENT VS TTM AVG
-44465.52%
CURRENT VS 3Y AVG
-549.69%
CURRENT VS 5Y AVG
-444.38%
CURRENT VS 10Y AVG
-435.02%
CURRENT VS 15Y AVG
-349.04%
CURRENT VS 20Y AVG
-364.61%
ABBV Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | — | -129.24% | -0.29% | 28.74% | 37.53% |
| UnitedHealth Group Incorporated (UNH) | $375.06B | 12.81% | 14.18% | 19.86% | 21.18% |
| Merck & Co., Inc. (MRK) | $295.39B | 34.70% | 35.83% | 26.05% | 27.71% |
| Johnson & Johnson (JNJ) | $570.51B | 32.87% | 26.27% | 31.76% | 29.75% |
| Amgen Inc. (AMGN) | $185.96B | 89.06% | 79.33% | 111.35% | 101.76% |
| Thermo Fisher Scientific Inc. (TMO) | $183.61B | 12.61% | 12.70% | 13.51% | 15.24% |
| Abbott Laboratories (ABT) | $158.94B | 12.51% | 20.32% | 18.59% | 17.97% |
| Gilead Sciences, Inc. (GILD) | $155.82B | 37.62% | 20.05% | 21.63% | 19.46% |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 16.02% | 15.07% | 13.91% | 13.46% |
| Pfizer Inc. (PFE) | $146.48B | 8.99% | 9.04% | 13.32% | 16.07% |
Return Analysis
ROE
-129.2%
ROA
3.1%
AbbVie Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AbbVie Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for AbbVie Inc. (ABBV)?
- The return on equity (ROE) for ABBV stock is -129.24%.
- Is AbbVie Inc.'s return on equity (ROE) high or low?
- AbbVie Inc.'s return on equity (ROE) of -129.24% is 444% below its 5-year average of 37.53%, near the low end of its 5-year range (-129.24%–128.66%).
- What is the TTM average return on equity (ROE) for AbbVie Inc. (ABBV)?
- The TTM average return on equity (ROE) for ABBV stock is -0.29%.
- What is the 3Y average return on equity (ROE) for AbbVie Inc. (ABBV)?
- The 3Y average return on equity (ROE) for ABBV stock is 28.74%.
- What is the 5Y average return on equity (ROE) for AbbVie Inc. (ABBV)?
- The 5Y average return on equity (ROE) for ABBV stock is 37.53%.
- What is the 10Y average return on equity (ROE) for AbbVie Inc. (ABBV)?
- The 10Y average return on equity (ROE) for ABBV stock is 38.58%.
- What is the 15Y average return on equity (ROE) for AbbVie Inc. (ABBV)?
- The 15Y average return on equity (ROE) for ABBV stock is 51.89%.
- What is the 20Y average return on equity (ROE) for AbbVie Inc. (ABBV)?
- The 20Y average return on equity (ROE) for ABBV stock is 48.84%.
AbbVie Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -129.24% |
| 2024-12-31 | 128.66% |
| 2023-12-31 | 46.94% |
| 2022-12-31 | 68.60% |
| 2021-12-31 | 74.91% |
| 2020-12-31 | 35.30% |
| 2019-12-31 | -96.45% |
| 2018-12-31 | -67.33% |
| 2017-12-31 | 104.16% |
| 2016-12-31 | 128.41% |
| 2015-12-31 | 130.39% |
| 2014-12-31 | 101.84% |
| 2013-12-31 | 91.90% |
| 2012-12-31 | 156.85% |
| 2011-12-31 | 28.77% |
| 2010-12-31 | 26.61% |
| 2009-12-31 | 0.00% |
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael